Health Care & Life Sciences » Biotechnology | Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
480.00
572.00
2,319.00
1,455.00
1,849.00
1,612
SG&A Expense
3,908.00
24,812.00
46,857.00
52,248.00
58,107.00
72,943
EBIT
3,454.00
24,402.00
45,350.00
52,396.00
58,354.00
73,081
Unusual Expense
1,653.00
984.00
2,573.00
63,214.00
1,000.00
5,157
Non Operating Income/Expense
96.00
-
370.00
762.00
2,700.00
4,361
Interest Expense
73.00
18.00
-
-
-
-
Pretax Income
5,276.00
25,404.00
47,553.00
114,848.00
56,654.00
73,877
Income Tax
-
-
100.00
1,101.00
507.00
1,250
Consolidated Net Income
5,276.00
28,634.00
47,453.00
113,747.00
56,147.00
72,627
Net Income
5,276.00
28,634.00
47,453.00
113,747.00
56,147.00
72,627
Net Income After Extraordinaries
5,276.00
28,634.00
47,453.00
113,747.00
56,147.00
72,627
Net Income Available to Common
5,276.00
28,634.00
47,453.00
113,747.00
56,147.00
72,627
EPS (Basic)
0.25
2.46
1.86
3.14
1.29
1.18
Basic Shares Outstanding
21,357.30
11,651.00
25,479.00
36,246.00
43,661.00
61,375
EPS (Diluted)
0.25
2.46
1.86
3.14
1.29
1.18
Diluted Shares Outstanding
21,357.30
11,651.00
25,479.00
36,246.00
43,661.00
61,375
EBITDA
3,428.00
24,240.00
44,538.00
50,793.00
56,258.00
71,331
Other After Tax Income (Expense)
-
3,230.00
-
-
-
-

About Adverum Biotechnologies

View Profile
Address
1035 O'Brien Drive
Menlo Park California 94025
United States
Employees -
Website http://www.adverum.com
Updated 07/08/2019
Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.